All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On November 17th 2016, the Lymphoma Hub published an article on a response by Marc C. Chamberlain to the Phase I/II NRG Oncology RTOG 0227 trial by Glass et al., published in May 2016. The main concerns raised by Chamberlain and subsequently addressed by Glass et al. were:
Glass et al. concluded their response by suggesting that going forward, clinicians should recruit for modest-sized Phase II trials that should be completed quickly in order to rapidly find treatments which may significantly improve patient outcome. These treatments should then be rapidly progressed to a Phase III trial in order to maximize treatment options, given the rarity of Primary CNS Lymphoma. However, in their opinion, their trial into methotrexate, temozolomide (TMZ) with rituximab, proceeded by hyperfractionated Whole-Brain Radiotherapy (hWBRT) remains a reasonable option for future trials to assess.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?